OnabotulinumtoxinA in Lower Limb Spasticity: Safety Results from a Pooled Analysis (P03.266)

CONCLUSIONS: OnabotulinumtoxinA treatment in lower limb spasticity was found to be safe and well-tolerated. Majority of AEs were considered not related to onabotulinumtoxinA and treatment-related AEs are consistent with the known mechanism of action of onabotulinumtoxinA.Supported by: Allergan, Inc.Disclosure: Dr. Earl has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Earl holds stock and/or stock options in AGN and GlaxoSmithKline, Inc. Dr. James has received personal compensation for activities with Allergan, Inc as an employee. Dr. Li has received personal compensation for activities with Allergan, Inc as an employee. Dr. Shi has received personal compensation for activities with Allergan, Inc as an employee. Dr. Demos has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Demos holds stock and/or stock options in Merck & Co., Inc. and Sanofi-Aventis Pharmaceuticals, Inc. Dr. Dimitrova has received personal compensation for activities with Allergan, Inc. as an employee.
Source: Neurology - Category: Neurology Authors: Tags: P03 Neural Repair Source Type: research